Cargando…

Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real‐world experience from a large comprehensive treatment centre in the US

INTRODUCTION: Surgery is frequently required in persons with haemophilia A (PwHA). Emicizumab, a bispecific, humanized monoclonal antibody, bridges activated factor (F) IX and FX. Management of patients undergoing surgery while receiving emicizumab is of clinical interest due to paucity of data. AIM...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lewandowska, Magdalena, Randall, Nicole, Bakeer, Nihal, Maahs, Jennifer, Sagar, Jeanne, Greist, Anne, Shapiro, Amy D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898816/ https://www.ncbi.nlm.nih.gov/pubmed/33245841 http://dx.doi.org/10.1111/hae.14212

Ejemplares similares

Low immunogenicity of emicizumab in persons with haemophilia A
por: Schmitt, Christophe, et al.
Publicado: (2021)

Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery
por: Jiménez‐Yuste, Victor, et al.
Publicado: (2021)

A phase IV, multicentre, open‐label study of emicizumab prophylaxis in people with haemophilia A with or without FVIII inhibitors undergoing minor surgical procedures
por: Escobar, Miguel, et al.
Publicado: (2022)

The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab
por: Carcao, Manuel, et al.
Publicado: (2019)

Cost‐effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK
por: Kragh, Nana, et al.
Publicado: (2022)

Emicizumab in acquired haemophilia A: about two clinical cases and literature review
por: Hansenne, Amandine, et al.
Publicado: (2021)

Anticoagulation for Stroke Prevention after Restoration of Haemostasis with Emicizumab in Acquired Haemophilia A
por: Al-Banaa, Kadhim, et al.
Publicado: (2021)

Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study
por: Kiialainen, Anna, et al.
Publicado: (2022)

Emicizumab dose up‐titration in case of suboptimal bleeding control in people with haemophilia A
por: Schmitt, Christophe, et al.
Publicado: (2022)

The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies
por: Skinner, Mark W., et al.
Publicado: (2021)

Optimizing maintenance dosing of emicizumab-kxwh as prophylaxis in hemophilia A: Dosing to product labeling while minimizing drug waste
por: D’Albini, Lesley, et al.
Publicado: (2023)

Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis
por: Pipe, Steven W., et al.
Publicado: (2023)

Serious bleeds in pediatric persons with hemophilia A on emicizumab prophylaxis
por: Garcia, Jessica, et al.
Publicado: (2023)

Peri‐operative hemostatic management of tooth extraction in patients with hemophilia A, with and without inhibitors, receiving emicizumab prophylaxis
por: Yagyuu, Takahiro, et al.
Publicado: (2022)

Management of surgery in persons with hemophilia A receiving emicizumab prophylaxis: data from a national hemophilia treatment center
por: Cohen, Omri, et al.
Publicado: (2023)

Emicizumab prophylaxis for people with hemophilia A: Waste estimation and the Brazilian perspective
por: Camelo, Ricardo Mesquita, et al.
Publicado: (2023)

Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human fviia) and emicizumab in congenital haemophilia A plasma
por: Grandoni, Jerry, et al.
Publicado: (2021)

Management of acquired haemophilia A in severe Covid‐19: Haemostatic bridging with emicizumab to keep the balance between bleeding and thrombosis
por: Gelbenegger, Georg, et al.
Publicado: (2022)

Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors
por: Kempton, Christine, et al.
Publicado: (2021)

Cerebellar hematoma in severe hemophilia with inhibitor on emicizumab prophylaxis: a case report
por: Albattat, Sami, et al.
Publicado: (2023)

Emicizumab in children: bleeding episodes and outcome before and after transition to Emicizumab
por: Glonnegger, Hannah, et al.
Publicado: (2022)

Study protocol for assessment of the coagulation potential of concomitantly used factor VIII concentrates in patients with haemophilia A with emicizumab prophylaxis (CAGUYAMA Study): a multicentre open-label non-randomised clinical trial
por: Takeyama, Masahiro, et al.
Publicado: (2023)

A multicentre, open‐label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors
por: Shima, Midori, et al.
Publicado: (2019)

Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies
por: Parnes, Aric, et al.
Publicado: (2021)

Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A
por: Zhou, Zheng-Yi, et al.
Publicado: (2020)

Target joint resolution in patients with haemophilia A receiving long‐term prophylaxis with BAY 94‐9027
por: Reding, Mark T., et al.
Publicado: (2020)

Emicizumab-induced photosensitivity
por: Asensi Cantó, Pedro, et al.
Publicado: (2022)

The profile of patients with haemophilia managed at a haemophilia treatment centre in Pretoria, Gauteng
por: Mafisa, Lethukuthula, et al.
Publicado: (2022)

Health‐related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors—Results from the HAVEN 2 study
por: Mancuso, Maria Elisa, et al.
Publicado: (2020)

AOZORA: long-term safety and joint health in paediatric persons with haemophilia A without factor VIII inhibitors receiving emicizumab – protocol for a multicentre, open-label, phase IV clinical study
por: Shima, Midori, et al.
Publicado: (2022)

Emicizumab state‐of‐the‐art update
por: Mahlangu, Johnny, et al.
Publicado: (2022)

Prophylaxis therapy with bypassing agents in patients with haemophilia A and inhibitors undergoing surgery: A cost analysis in Spain
por: Mareque, María, et al.
Publicado: (2020)

Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China
por: Liu, Guoqing, et al.
Publicado: (2022)

Management and Outcomes of Invasive Procedures in Individuals with Hemophilia A on Emicizumab Prophylaxis: A Single Center Experience
por: Rener, Karla, et al.
Publicado: (2023)

Haemophilia A: Pharmacoeconomic Review of Prophylaxis Treatment versus On-Demand
por: Unim, Brigid, et al.
Publicado: (2015)

Medication Adherence for Haemophilia Patients: Outcome of Prophylaxis Treatment Intervention
por: Mokhtar, Fadzlin Mohd, et al.
Publicado: (2021)

Characterization of Anti-Emicizumab Antibodies Using Repository Samples Obtained in Clinical Studies of Emicizumab Conducted in Japan
por: Matsumoto, Naoki, et al.
Publicado: (2023)

Diagnosis and treatment of chronic synovitis in patients with haemophilia: consensus statements from the Italian Association of Haemophilia Centres
por: Di Minno, Matteo Nicola Dario, et al.
Publicado: (2021)

S300: ASSESSMENT OF JOINT HEALTH IN PATIENTS RECEIVING PROPHYLAXIS FOR HAEMOPHILIA A IN FIVE EUROPEAN COUNTRIES: A CROSS-SECTIONAL SURVEY
por: De la Corte‐rodriguez, Hortensia, et al.
Publicado: (2023)

Emicizumab prophylaxis in a Korean child with severe hemophilia A and high titer inhibitor: a case report
por: Ahn, Ji Hyun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_blafpjor5kv6etvriebdgrbrl9